

Natasa Bratina

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1526005/publications.pdf>

Version: 2024-02-01

46
papers

2,435
citations

279701

23
h-index

265120

42
g-index

47
all docs

47
docs citations

47
times ranked

2821
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of Continuous Glucose Monitoring on Hypoglycemia in Type 1 Diabetes. <i>Diabetes Care</i> , 2011, 34, 795-800.	4.3	427
2	Nocturnal Glucose Control with an Artificial Pancreas at a Diabetes Camp. <i>New England Journal of Medicine</i> , 2013, 368, 824-833.	13.9	397
3	Trends and cyclical variation in the incidence of childhood type 1 diabetes in 26 European centres in the 25-year period 1989–2013: a multicentre prospective registration study. <i>Diabetologia</i> , 2019, 62, 408-417.	2.9	327
4	MD-Logic Overnight Control for 6 Weeks of Home Use in Patients With Type 1 Diabetes: Randomized Crossover Trial. <i>Diabetes Care</i> , 2014, 37, 3025-3032.	4.3	158
5	Universal Screening for Familial Hypercholesterolemia in Children. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1250-1257.	1.2	124
6	Temporal trends in diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes between 2006 and 2016: results from 13 countries in three continents. <i>Diabetologia</i> , 2020, 63, 1530-1541.	2.9	86
7	Faster Compared With Standard Insulin Aspart During Day-and-Night Fully Closed-Loop Insulin Therapy in Type 1 Diabetes: A Double-Blind Randomized Crossover Trial. <i>Diabetes Care</i> , 2020, 43, 29-36.	4.3	68
8	Improved Metabolic Control in Pediatric Patients with Type 1 Diabetes: A Nationwide Prospective 12-Year Time Trends Analysis. <i>Diabetes Technology and Therapeutics</i> , 2014, 16, 33-40.	2.4	67
9	Closed-loop glucose control in young people with type 1 diabetes during and after unannounced physical activity: a randomised controlled crossover trial. <i>Diabetologia</i> , 2017, 60, 2157-2167.	2.9	64
10	ISPAD Clinical Practice Consensus Guidelines 2018: Management and support of children and adolescents with type 1 diabetes in school. <i>Pediatric Diabetes</i> , 2018, 19, 287-301.	1.2	56
11	Prevalence of underweight, overweight, and obesity in children and adolescents with type 1 diabetes: Data from the international SWEET registry. <i>Pediatric Diabetes</i> , 2018, 19, 1211-1220.	1.2	55
12	Possibilities and challenges of a large international benchmarking in pediatric diabetology-The SWEET experience. <i>Pediatric Diabetes</i> , 2016, 17, 7-15.	1.2	43
13	High-risk genotypes HLA-DR3-DQ2/DR3-DQ2 and DR3-DQ2/DR4-DQ8 in co-occurrence of type 1 diabetes and celiac disease. <i>Autoimmunity</i> , 2016, 49, 240-247.	1.2	43
14	Fear of hypoglycemia, anxiety, and subjective well-being in parents of children and adolescents with type 1 diabetes. <i>Journal of Health Psychology</i> , 2019, 24, 209-218.	1.3	43
15	MD-Logic overnight type 1 diabetes control in home settings: a multicentre, multinational, single blind randomized trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 553-561.	2.2	37
16	Add-on therapy with dapagliflozin under full closed loop control improves time in range in adolescents and young adults with type 1 diabetes: The DAPADream study. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 599-608.	2.2	36
17	A description of clinician reported diagnosis of type 2 diabetes and other non-type 1 diabetes included in a large international multicentered pediatric diabetes registry (SWEET). <i>Pediatric Diabetes</i> , 2016, 17, 24-31.	1.2	35
18	Persistent heterogeneity in diabetes technology reimbursement for children with type 1 diabetes: The SWEET perspective. <i>Pediatric Diabetes</i> , 2019, 20, 434-443.	1.2	35

#	ARTICLE	IF	CITATIONS
19	DREAM5: An open-label, randomized, cross-over study to evaluate the safety and efficacy of day and night closed-loop control by comparing the MDLogic automated insulin delivery system to sensor augmented pump therapy in patients with type 1 diabetes at home. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 822-828.	2.2	29
20	Extracellular Vesicles Derived Human-miRNAs Modulate the Immune System in Type 1 Diabetes. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 202.	1.8	29
21	Non-adjunctive flash glucose monitoring system use during summer-camp in children with type 1 diabetes: The free-summer study. <i>Pediatric Diabetes</i> , 2018, 19, 1285-1293.	1.2	28
22	Acute Hyperglycemia and Spatial Working Memory in Adolescents With Type 1 Diabetes. <i>Diabetes Care</i> , 2020, 43, 1941-1944.	4.3	28
23	Lived Experience of Advanced Hybrid Closed-Loop Versus Hybrid Closed-Loop: Patient-Reported Outcomes and Perspectives. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, 857-861.	2.4	28
24	International comparison of glycaemic control in people with type 1 diabetes: an update and extension. <i>Diabetic Medicine</i> , 2022, 39, e14766.	1.2	28
25	Continuous glucose monitoring use and glucose variability in pre-school children with type 1 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2019, 147, 76-80.	1.1	25
26	Natural History of Obesity Due to POMC, PCSK1, and LEPR Deficiency and the Impact of Setmelanotide. <i>Journal of the Endocrine Society</i> , 2022, 6, bvac057.	0.1	19
27	Two Cases With an Early Presented Proopiomelanocortin Deficiency – A Long-Term Follow-Up and Systematic Literature Review. <i>Frontiers in Endocrinology</i> , 2021, 12, 689387.	1.5	17
28	Association of Glycemic Control and Cell Stress With Telomere Attrition in Type 1 Diabetes. <i>JAMA Pediatrics</i> , 2018, 172, 879.	3.3	15
29	Metabolic control, ApoE genotypes, and dyslipidemia in children, adolescents and young adults with type 1 diabetes. <i>Atherosclerosis</i> , 2018, 273, 53-58.	0.4	13
30	Impact of attention deficit hyperactivity disorder on metabolic control in adolescents with type 1 diabetes. <i>Journal of Psychosomatic Research</i> , 2019, 126, 109816.	1.2	11
31	The Role of Epigenetic Modifications in Late Complications in Type 1 Diabetes. <i>Genes</i> , 2022, 13, 705.	1.0	11
32	Type 1 Diabetes in the Young: Organization of two National Centers in Israel and Slovenia / Sladkorna Bolezen Tipa 1 Pri Otrocih in Mladostnikih: Organizacija Dela V Dveh Nacionalnih Centrih V Izraelu in Sloveniji. <i>Zdravstveno Varstvo</i> , 2015, 54, 139-145.	0.6	8
33	Dual Role of PTPN22 but Not NLRP3 Inflammasome Polymorphisms in Type 1 Diabetes and Celiac Disease in Children. <i>Frontiers in Pediatrics</i> , 2019, 7, 63.	0.9	8
34	Support Group for Parents Coping with Children with Type 1 Diabetes / Skupina Za Starše Kot Podpora Druščinam Pri soočanju Z Otrokovo Sladkorno Boleznijo Tipa 1. <i>Zdravstveno Varstvo</i> , 2015, 54, 79-85.	0.6	7
35	Insulin pumps and continuous glucose monitoring (CGM) in preschool and school-age children: how schools can integrate technology. <i>Pediatric Endocrinology Reviews</i> , 2010, 7 Suppl 3, 417-21.	1.2	6
36	Health Care System for Children and Adolescents in Slovenia. <i>Journal of Pediatrics</i> , 2016, 177, S173-S186.	0.9	4

#	ARTICLE	IF	CITATIONS
37	Annual Psychological Screening in Youth and Young Adults with Type 1 Diabetes / Letno Presejalno PsiholoÅžko Testiranje Pri Mladostnikih in Mladih Odraslih S Sladkorno Boleznijo Tipa 1. Zdravstveno Varstvo, 2015, 54, 103-111.	0.6	3
38	Carer's Attachment Anxiety, Stressful Life-Events and the Risk of Childhood-Onset Type 1 Diabetes. Frontiers in Psychiatry, 2021, 12, 657982.	1.3	3
39	Immune Intervention in Type 1 Diabetes. Diabetes Technology and Therapeutics, 2019, 21, S-95-S-100.	2.4	2
40	Immune Interventions for Type 1 Diabetes Mellitus. Diabetes Technology and Therapeutics, 2017, 19, S-74-S-81.	2.4	1
41	Validation of the Lifetime Incidence of Traumatic Events (LITE-S/P) Questionnaires in Children and Adolescents in Slovenia. Frontiers in Psychiatry, 2021, 12, 665315.	1.3	1
42	Immune Intervention for Type 1 Diabetes. Diabetes Technology and Therapeutics, 2018, 20, S-86-S-93.	2.4	0
43	Immune Intervention in Type 1 Diabetes. Diabetes Technology and Therapeutics, 2020, 22, S-141-S-148.	2.4	0
44	Immune Intervention in Type 1 Diabetes. Diabetes Technology and Therapeutics, 2021, 23, S-179-S-184.	2.4	0
45	Reye Syndrome with Severe Hyperammonemia and a Good Neurological Outcome. American Journal of Case Reports, 2021, 22, e932864.	0.3	0
46	Immune Intervention in Type 1 Diabetes. Diabetes Technology and Therapeutics, 2022, 24, S-184-S-189.	2.4	0